Clinical study of rhILª²11 on severe thrombocytopenia in cancer patients after chemotherapy

    ZHANG Yanª²Jun, REN Jun, FAN Li, LIU Wenª²Chao, YOU Xiangª²Hui, HUANG Ruoª²Yu£¬ HUANG Ying£¬ SI Xiaoª²Ming, PAN Boª²Rong

    Center of Clinical Oncology, Xijing Hospital, Fourth Military Medical University, Xi¡¯an 710033, China

    ¡¾Abstract¡¿ AIM: To evaluate the influence of recombinant human interleukin 11 (rhILª²11) on thrombocytes in cancer patients after chemotherapy. METHODS: By using open, self crossª²over and negativeª²control methods, the patients were treated by two cycles: cycle A and cycle B. In cycle A, the firstª²cycle chemotherapy, the patients were treated only with chemotherapy without rhILª²11. In cycle B, the secondª²cycle chemotherapy, the patients were treated with rhILª²11 after the same chemotherapy as that in the first cycle. 50 ¦Ìg/kg of rhILª²11 was administered subcutaneously once daily 24 h after the completion of the chemotherapy in cycle B. The administration of rhILª²11 lasted for at least 7 d and at most 14 d, and would cease if the patient¡¯s platelet count was ¡Ý3¡Á1011/L for two successive days. RESULTS: Of the 30 patients enrolled in this study, 2 were excluded because of the platelet transfusion in cycle B. The other 28 patients were eligible for the evaluation of curative effects and all the 30 patients were eligible for the evaluation of toxicity. There was not statistics difference of PLT between cycle A and cycle B before chemotherapy, but from the 7th d to the 21st d after chemotherapy, the patients in cycle B had a significant higher platelet level than the patients in cycle A. The administration of rhILª²11 also prolonged the duration of increment of PLT counts and shortened the duration of the PLT counts decline. No toxicity to WBC was observed in both cycles. The mean value of Hb was lower on the eighteenth day in A group than that in B group. The toxicities mainly included fever, fatigue, nausea, ache of injected skin, edema, headache and myalgia, but they could be well tolerated. CONCLUSION: rhILª²11 has strong thrombopoietic activity and can be wellª²tolerated for cancer patients undergoing chemotherapy. ......